** Drugmaker GlaxoSmithKline down 3 percent, hit bytrading ex-dividend and downgrade to "neutral" from "buy" bybrokerage UBS
** UBS analyst Alexandra Hauber says GSK's 2020 pharmaoutlook implies a sharp deterioration of pharma profit margin,excluding the HIV business ViiV, with ViiV blockbuster profitsappearing to cross-subsidise low profits elsewhere
** Britain's biggest pharmaceuticals group set out itsstrategy and long-term goals last week, following a re-shapingof the group after $20 billion-plus asset swap with Novartis (RM: ben.hirschler.thomsonreuters.com@reuters.net)
Glaxosmithkline (GSK)
